Exogenous group G Streptococcus endophthalmitis following intravitreal ranibizumab injection

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1399-1402

  Kugu, Suleyman ^a   Sevim, Mehmet Sahin ^b   Kaymak, Nilufer Zorlutuna ^a   Erdogan, Gurkan ^c   Kandemir, Baran ^a   Dogan, Omer Kamil ^d  

^a Kartal Lutfi Kirdar Training and Research Hospital   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c UMRANIYE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d World Eye Hospital   (Turkey)

Author keywords

Endophthalmitis; Group; Intravitreal injection; Streptococcus

Indexed keywords

CEFAZOLIN; CYCLOPENTOLATE; GENTAMICIN; RANIBIZUMAB;

ADULT; ARTICLE; BACTERIUM CULTURE; CASE REPORT; CHEMOSIS; CONJUNCTIVAL HYPEREMIA; DISEASE DURATION; DRUG RESPONSE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ENDOPHTHALMITIS; EYE PAIN; EYE REDNESS; EYELID EDEMA; HEART ARREST; HEART INFARCTION; HUMAN; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; RESUSCITATION; RETINA EDEMA; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; STREPTOCOCCUS GROUP G; STREPTOCOCCUS INFECTION; SUBRETINAL NEOVASCULARIZATION; THORAX PAIN; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 84865824573     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S31721     Document Type: Article

References (29)

1. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007; 144(4):627-637.
2. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6): 502-508.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1419-1431.
4. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
5. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
6. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subject with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(9):1731-1739.
7. Chhatwal GS, Mcmillan DJ, Talay SR. Pathogenicity factors in group C and G streptococci. In: Fischetti VA, editor. Gram-Positive Pathogens (2nd edition). Washington, DC: ASM Press; 2006:213-221.
8. Auckenthaler R, Hermans PE, Washington JA 2nd. Group G streptococcal bacteremia: clinical study and review of the literature. Rev Infect Dis. 1983;5(2):196-204.
9. Goh ES, Liew GC. Traumatic bleb-associated Group-G beta-haemolytic Streptococcus endophthalmitis. Clin Experiment Ophthalmol. 2008; 36(6):580-581.
10. Suemori S, Sawada A, Kamori S, Mochizuki K, Ohkusu K, Takemura H. Case of endogenous endophthalmitis caused by Streptococcus equisimilis. Clin Ophthalmol. 2010;19(4):917-918.
11. Fitnak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28(10):1395-1399.
12. Bhavsar AR, Googe JM Jr, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009; 127(12):1581-1583.
13. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology. 2010;117(2):298-302.
14. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98(12):1769-1775.
15. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(Suppl 5):S3-S19.
16. Woo SJ, Han JM, Ahn J, et al. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina. 2012;32(4):667-671.
17. Mahajan VB, Elkins KA, Russell SR, et al. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina. 2011;31(1):31-35.
18. Davis RP, Schefler AC, Murray TG. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol. 2010;4:703-707.
19. Sylvetsky N, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Bacteremia due to beta-hemolytic Streptococcus group G: increasing incidence and clinical characteristics of patients. Am J Med. 2002; 112(8):622-626.
20. Wickramasinghe N, Harris K. Bilateral endophthalmitis as a primary manifestation of Streptococcus dysgalactiae endocarditis and the role of 16S rDNA polymerase chain reaction in identification. Diagn Microbiol Infect Dis. 2010;67(2):185-187.
21. Gopalamurugan AB, Wheatcroft S, Hunter P, Thomas MR. Bilateral endophthalmitis and ARDS complicating group G streptococcal endocarditis. Lancet. 2005;366(9502):2062.
22. Verweij PE, Rademakers AJ, Koopmans PP, Meis JF. Endophthalmitis as presenting symptom of group G streptococcal endocarditis. Infection. 1994;22(1):56-57.
23. Ziakas NG, Tzetzi D, Boboridis K, Georgiadis NS. Endogenous group G Streptococcus endophthalmitis following a dental procedure. Eur J Ophthalmol. 2004;14(1):59-60.
24. Song A, Scott IU, Flynn HW Jr, Budenz DL. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology. 2002;109(5):985-991.
25. Farber BP, Weinbaum DL, Dummer JS. Metastatic bacterial endophthalmitis. Arch Intern Med. 1985;145(1):62-64.
26. Miller KM, Glasgow BJ. Bacterial endophthalmitis following sutureless cataract surgery. Arch Ophthalmol. 1993;111(3):377-379.
27. Ritterband DC, Shah MK, Buxton DJ, Intal MC, Gutherie DS, Seedor JA. A devastating ocular pathogen: beta-streptococcus Group G. Cornea. 2000;19(3):297-300.
28. Rogers NK, Fox PD, Noble BA, Kerr K, Inglis T. Aggressive management of an epidemic of chronic pseudophakic results and literature survey. Br J Ophthalmol. 1994;78(2):115-119.
29. Maalouf F, Abdulaal M, Hamam RN. Chronic postoperative endophthalmitis: a review of clinical characteristics, microbiology, treatment strategies, and outcomes. Int J Inflam. 2012:Article ID 313248.